Q2 2025 Devyser Diagnostics AB Earnings Call Transcript
Key Points
- Devyser Diagnostics AB (FRA:OL0) reported a record revenue of SEK67 million for Q2 2025, marking a 27% growth compared to the same quarter last year.
- The company achieved a gross margin of 84%, demonstrating strong profitability.
- EBIT reached a record SEK5.5 million, showing significant improvement from the previous quarter.
- The reorganization plan has been completed, resulting in a healthier cost structure and improved efficiency across the organization.
- Devyser Diagnostics AB (FRA:OL0) launched several new products, including the HLA loss product and genomic blood group typing product, which have received positive feedback and are gaining traction in the market.
- The cash flow for the quarter was negative at minus SEK14.8 million, indicating that it has not yet caught up with the strong EBIT development.
- Sales in the Asia Pacific region were lower compared to the previous year, highlighting regional sales fluctuations.
- Direct sales showed a softer quarter, particularly impacted by performance in the Italian market.
- The company faces challenges in the US market with the need for additional samples to complement the MolDX submission for a positive reimbursement decision.
- There are ongoing investments in product development, which continue to impact cash flow and require careful cash management.
Good day and welcome to the visor Q2 2025 earnings call. I'm Fredrik Dahl. I'm the acting CEO of Devyser and would like to thank you everyone for joining our call today.
On the call today, we have, in addition to myself, also our CFO, Sabina Berlin; and our Chief Commercial Officer, Theis Kipling.
I will start with a short summary of our quarterly results and then recap our recent activities that have resulted in an improved efficiency overall for the organization. I will then give an update on the recent product launches and present some additional highlights from the quarter before handing over to Sabina for a more detailed review of our financial results in Q2 2025, and then to tie for an update on our recent commercial activities.
We are turning the company around on a path to profitability. We had another record quarter based on revenue with SEK67 million second sales representing a growth of around 27% compared to Q2 last year. Gross margins came in at 84%. What we are most proud of is the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
